BRICANYL
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Mar 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRICANYL is an injectable small-molecule bronchodilator approved in 1974 for respiratory indications. The product is a mature, established therapy administered via injection. Specific mechanism of action and indicated conditions are not detailed in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30) suggests a consolidating portfolio role; team focus likely shifting to lifecycle defense or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Started Mar 2015
95 enrolled
Asthma
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Started Sep 2009
66 enrolled
Exercise Induced Asthma
Career Relevance
Zero linked job openings indicate limited hiring activity; roles on BRICANYL are primarily maintenance-focused rather than growth-oriented. Career progression on this product may be constrained by the LOE lifecycle stage and Sanofi's portfolio prioritization.
Brand Manager
Worked on BRICANYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.